Abstract: For people starting off in the field of gene therapy, the encountered terminology is often quite confusing. Moreover, the background on basic virology may be modest. The following introduction provides a head start to any novice willing to gain more in-depth knowledge on the subject. The development of gene therapy is also addressed from a historical perspective.
INTRODUCTION
For people starting off in the field of gene therapy, the encountered terminology is often quite confusing. Moreover, the background on basic virology may be modest. The following introduction provides a headstart to any novice willing to gain more in-depth knowledge on the subject.
TERMINOLOGY (SEE ALSO TABLE 1)
Prokaryotic cells, such as bacteria, lack cell organelles and a nucleus but are surrounded by a cell wall. They have a metabolism that is distinct from eukaryotic cells, which have cell organelles and a nucleus and are surrounded by a cell membrane. Eukaryotic cells have a limited life span; primary cells can only be propagated for a limited amount of passages. That is why immortalized cell lines, which are originally derived from tumors and constructed in the laboratory, are used. These cell lines can have different origins (insect, mammalian, human) . When targeting human cells in gene therapy, one has to make a clear distinction between somatic and germ cells. The somatic cells are the cells that make up the different organs of the human body. From a moral point of view, gene transfer in somatic cells is allowed, especially for curative purposes. The germ cells are the cells involved in reproduction. A genetic modification of those cells will result in genetically modified gametes and after fecundation in genetically altered offspring. Altering the human species by genetic modification of germ cells is not allowed and care should be taken to avoid inadvertent transduction of germ cells.
A plasmid is a circular form of extrachromosomal DNA that can be propagated in bacteria. A eukaryotic expression vector (often called an expression vector for short) is a plasmid that drives the expression of proteins from a eukaryotic promoter inside eukaryotic cells; through the presence of a bacterial origin of replication (ori) these plasmids can be propagated in bacteria as well. A viral *Address correspondence to this author at the Laboratory for Molecular Virology and Gene Therapy, Rega Institute for Medical Research, KU Leuven Minderbroedersstraat 10, B-3000 Leuven Flanders, Belgium; Tel: 32-1633 Tel: 32- -2183 Fax: 32-1633 Fax: 32- -2131 E-mail: zeger.debyser@uz.kuleuven. ac.be vector is a protein particle derived from a replicative virus that contains genetic information in the form of RNA or DNA. A viral envelope may be present as well.
Gene transfer is the introduction of genetic material in cells that can be of different origin (bacteria, yeast, plants, insect cells, mammalian cells); gene therapy is the introduction of genetic material in cells with the purpose of curing a disease (e.g. X-SCID, hemophilia). Gene therapy typically involves gene transfer into animal models and patients. Expression of a disease protein in a cell is thus the result of a gene transfer and not of a gene therapy experiment. DNA vaccination is gene transfer into animal models and humans in order to prevent a disease by eliciting an immune response against the expressed gene product.
Gene transfer of DNA in bacteria, to express a recombinant protein in E. coli for example, is called transformation, whereas gene transfer of DNA in eukaryotic cells is called transfection. Using a viral vector (as defined above) to transfer a gene into a cell is referred to as transduction. When a virus that typically replicates and spreads into neighbouring cells, mediates a transfer of genes belonging to its own genome or extra genes it may carry, we talk about infection. It is important to make the following distinction: a viral vector transduces the target cells as opposed to the wild type (parental) virus that infects the target cells.
AN INTRODUCTION TO VIROLOGY
Viruses are small particles (10-300 nm) that depend on a host cell for their replication. This host cell can be a bacterium (for a bacteriophage), a plant cell or an animal cell. Viruses are composed of nucleic acids, which contain the genetic information of the virus, inside a protein shell named "capsid". Some viruses are additionally surrounded by an envelope: a lipid membrane containing glyco-or lipoproteins, derived from the membrane of the host cell. This characteristic distinguishes enveloped from nonenveloped viruses. Viruses contain RNA or DNA that can be single-or double-stranded. The classification of viruses is traditionally based on nucleic acid type and presence or absence of an envelope ( Table 2) . Single-stranded RNA Viral replication always more or less depends on the host cell metabolism. The consecutive stages of the viral replication cycle can be schematically arranged. The early stages are similar for most viruses. The later stages of replication vary greatly between RNA and DNA viruses. The first step is the adsorption of the virus to the target cell. It involves interactions between the capsid or envelop of the virus and components of the cell membrane, called receptors that are often virus-specific. Those receptors have a role during the normal cell metabolism. Adsorption is followed by entry. There are two main mechanisms by which this can be realized: fusion of (enveloped) virus and cell membranes or receptor-mediated endocytosis. Endocytosis is followed by uncoating in the lysosome and the same goes for fusion, although only partial uncoating takes place there.
For DNA viruses ( Fig. 1) , viral replication can be divided into an early and a late phase. The early phase takes place prior to DNA replication. Early mRNA's are synthesized using the cellular RNA polymerase. They encode early, nonstructural proteins such as replication enzymes. After DNA replication, late mRNA's are synthesized. These encode the structural proteins of the virus. DNA replication in the nucleus is carried out by an enzyme complex of cellular and viral origin. The structural proteins are transported into the nucleus, where the new viral particles are assembled. Virus is then set free by lysis of the infected cell. 
Gag
Group specific antigen, a polyprotein made up of the viral structural protein matrix (MA), capsid (CA) and nucleocapsid (NC).
Pol
Polymerase, a polyprotein containing the viral enzymes protease (PR), reverse transcriptase (RT) and integrase (IN).
Env
Envelope, the retroviral surface protein that directs binding of the virion to a specific cellular receptor.
amphotropic An amphotropic env protein can bind to a wide variety of cells (broad tropism).
ψ Packaging signal, region in the viral RNA that is required for incorporating the RNA in the virion.
packaging cell
Cell that encodes viral proteins (gag, pol, env), but produces empty viral particles since ψ has been deleted. The process of viral replication is very efficient. One infectious particle leads to formation of 10 5 to 10 7 new virus particles, although not all particles formed will be infectious. Replication of adenoviruses and herpesviruses is characterized by an additional immediate-early phase in the replication cycle. Replication of poxviruses (such as vaccinia) occurs in the cytoplasm using a viral RNA polymerase. During viral replication, host cell metabolism is suppressed to favor replication of the virus.
For RNA viruses, different replication mechanisms exist after adsorption, entry and uncoating. Positive strand viruses, such as picornaviruses, carry a single-stranded RNA genome that functions as mRNA. The mRNA is translated into a large polyprotein that is subsequently cleaved into the different structural and enzymatic proteins. Important is the viral RNA-dependent RNA polymerase, which drives the machinery needed for copying the genomic RNA. From the positive strand a negative strand is made, which serves as a template for the synthesis of new positive RNA strands that are assembled together with the structural proteins into new viral particles. The negative strand RNA viruses, such as the myxo and paramyxoviruses, contain an RNA polymerase that copies the negative RNA genome into a positive copy that serves as mRNA. In the myxoviruses the genome is composed of 8 fragments, each encoding one gene; each fragment is copied separately.
Retroviruses carry an RNA-dependent DNA polymerase (reverse transcriptase) that copies the two copies of the RNA genome into one double-stranded DNA molecule. This DNA molecule is then integrated in the host chromosome through the viral integrase. Consecutively, cellular RNA polymerase transcribes the viral genes into mRNA's that encode for structural and enzymatic viral proteins. The viral DNA is stably integrated in the host cell and copied together with the genome of the cell upon cell division.
Most RNA viruses leave the host cell by a budding process. At budding, the viral particles are surrounded by part of the cell membrane containing cellular and viral membrane proteins. 
WHAT VECTOROLOGY IS ABOUT?
Viruses have evolved by Darwinian selection over billions of years into efficient vehicula infecting cells and introducing their genetic material. Vectors derived from replicating viruses are the most frequently used vehicles to transfer genes into somatic cells. In a non-replicating viral vector, the viral genome has been deleted and replaced by the genes of interest. In result thereof, the vector will enter the target cell and introduce the therapeutic genes but will no longer be able to propagate itself due to the absence of the viral genome. Inadvertently, vectors may arise during production that has acquired the genes required for replication through recombination. These replicationcompetent vectors may have the capacity to spread to other cells. Production of viral vectors should be monitored for accidental contamination with replication competent vectors. For the different viral vector systems, strategies have been designed that limit the chance of recombination and assays for the detection of recombinants have been developed. Retroviral vectors, derived from murine oncoretroviruses, were the first vectors used for experimental gene transfer in vitro and in vivo (and in patients). To date, vector systems have been derived from different viruses. All viral vectors have their advantages and disadvantages so that no single viral vector is applicable to all purposes in gene transfer ( Table 3) . Choice of viral vector is determined by the size of the gene of interest, the required duration of gene expression, the target cell and biosafety issues. In the following chapters, different viral vector systems will be explained starting from the virology of the parental virus. Those vector properties, which affect biosafety (for the scientist, the patient and the environment) will be accentuated.
EPIDEMIOLOGICAL ASPECTS OF THE VIRAL INFECTION
Viral infection of humans can have different consequences. Infection with viruses such as the virus of common cold (rhinovirus) leads to an acute self-limiting infection. An acute infection can be followed by a latent phase as seen in herpes viruses and many hepatitis viruses that maintain their viral DNA under episomal conditions or in integrated form in the nucleus of the target cell. The latency phase can be interrupted by acute exacerbations. A typical example is recurrent herpes labialis caused by herpes simplex or shingles, the exacerbation of latent varicella zoster virus. In the case of the human immunodeficiency virus (HIV) -a retrovirus -chronic infection will lead to a progressive destruction of the host lymphocytes, which will ultimately lead to immune deficiency. The pathogenicity of viruses is determined by their own (lytic) replication cycle but also by the immune response of the host that is destroying cells, which carry viral epitopes. Viruses with a latency phase have developed different tricks to evade the immune response of the host.
Viruses can be transmitted directly or indirectly. Determining factors are the nature of the virus, the site of infection and environmental conditions. Resistance of viruses against environmental conditions varies. Very resistant are viruses that infect their host through the gastrointestinal tractus (faeco-oral contamination) such as enteroviruses, hepatitis A and reoviruses. These viruses are liable to survive in surface waters for a long time and cause epidemics, which can be prevented by a proper hygiene. HIV, hepatitis B and C virus are transmitted through sexual intercourse and contamination with blood products (blood transfusion, intravenous drug use). Viruses that cause respiratory diseases can be spread by aerosol. Adenovirus is very stable in the environment at temperatures below 37°C and at pH 6-9. Arboviruses (arthropode born) are spread by blood-sucking insects. An important feature is that all enveloped viruses can be inactivated by ether or detergents. They are also sensitive to complement-based inactivation. Antiviral defense mechanisms can be non-specific or specific. Interferon, for example, is produced by the virusinfected cell and can protect neighbouring cells against viral infection. This particular immune reaction is based on production of virus-specific antibodies and stimulation of the cytocidal effect of cytotoxic lymphocytes. Cellular immunity plays an important role in non-cytolytic infections. Immune suppression on the other hand, can lead to exacerbations of latent virus infections.
GENE THERAPY THEN AND NOW

Retroviral Vectors
Virologists have been at the forefront of many new developments in molecular biology. Oncogenes and tumorsuppressor genes were first discovered in the context of RNA and DNA tumor viruses, respectively. Likewise, retrovirology has been the historical base for vectorology (For reviews see Miller, 1997 or Friedmann, 1999 . In 1981, several groups independently reported the development of replication-defective, recombinant, murine retrovirus-based retroviral vectors in order to correct gene defects in mammalian cells (Shimotohno and Temin, 1981 ; Tabin et al., 1982; Wei et al., 1981) . The first demonstration of the correction of a genetic defect (of Lesch Nyhan syndrome) in cell culture conditions was in 1983 (Willis et al., 1984) . Clinical trials on gene transfer into humans began in 1989-90. After a first gene marking study, to determine if a foreign gene could be transferred ex vivo into human tumorinfiltrating lymphocytes (Rosenberg et al., 1990) , a clinical trial was carried out with patients suffering from severe combined immunodeficiency disorder (SCID) due to a deficiency in the enzyme adenosine deaminase (Ada). Using a retroviral vector the normal Ada gene was transferred into patients' T cells. Evidence for gene transfer and gene expression was evident in these studies, and there were some indications of clinical efficacy.
High Days of Clinical Trials: 1990-1995
These first clinical trials got a tremendous amount of media attention. They were the start of many other human gene therapy trials over the following years. In the meantime, other viral vector systems had been developed (Table 3 ) including vectors derived from human adenovirus, herpes simplex virus and adeno-associated virus (Mulligan, 1993; Smith, 1995; Berns and Giraud, 1995) . Non-viral gene transfer systems, such as liposomes were designed as well. All possible viral and non-viral vector systems were tested for gene therapy applicability on many forms of cancer, metabolic diseases such as cystic fibrosis, familial hypercholesterolaemia, hemophilia, neuromuscular disorders and AIDS. By 1995, over 200 approved gene therapy studies were on their way.
Orkin-Motulsky Report 1995: "STOP, Go Back to the Bench"
By fall 1995, it became clear that the expectations of clinical benefit due to gene therapy had been too high and premature. The NIH committee chaired by Drs Stuart Orkin and Arno Motulsky stated that the clinical potential of human gene therapy with current vectors had been overstated to the public and that they recommended a renewed emphasis on the basic study of vector design. A second committee, chaired by Dr. I. Verma, proposed changes to the review process of clinical studies on gene therapy. As a result of the disappointing clinical results and the renewed efforts made to improve vector design, new generations of vectors were developed such as lentiviral vectors and gutless adenoviral vectors. It was clear, though, that no single vector was going to be perfect. Each vector had advantages and disadvantages, making it appropriate for one particular application. Finally, strict regulations for the approval process of clinical protocols came into existence.
1999-2001: Cautious Optimism
During the fall of 1999, the gene therapy field was struck by the Jesse Gelsinger case. Jesse was the first patient who died during a gene therapy trial at the University of Pennsylvania, following an intravenous injection of a high dosage of adenoviral vector from an older generation. Afterwards, it became clear that the death should rather be ascribed to "malpractice" than to inherent risks associated with viral vector technology. Nevertheless, this turmoil pointed again to the need for close scrutiny of gene therapy trials and public awareness of side-effects during ongoing trials (Teichler Zallen, 2000; Somia and Verma, 2000) .
In spring 2000, the gene therapy field applauded the first demonstration of unambiguous clinical benefit following retroviral vector-mediated ex vivo gene therapy on two babies suffering from X-linked SCID (Cavazzana-Calvo et al., 2000) . Promising clinical trials for cancer (using p53-based gene therapy) and hemophilia are being developed as we speak.
Leukemia in 2 out of 11 children in this trial has been attributed to the insertion of the retroviral vector in the LMO2 gene, again pointing to the caution required for clinical gene therapy trials.
